logo
logo

Appili Therapeutics Announces Additional Funding for Its ATI-1701 Biodefense Program

Oct 27, 2020•over 4 years ago

Amount Raised

$6 Million

HalifaxBiotechnologyScience And EngineeringHealth Care

Description

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced updates for the continued development of its ATI-1701 biodefense vaccine program. Appili has entered into an agreement with Ology Biosciences, a biologics contract development and manufacturing organization (CDMO), under which Ology will manufacture ATI-1701, a novel live attenuated tularemia vaccine candidate. The U.S

Company Information

Company

Appili Therapeutics

Location

Halifax, Nova Scotia, Canada

About

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the antiviral Avigan/Reeqonus for the worldwide treatment and prevention of COVID-19. The Company is also advancing a diverse range of anti-infectives, including a broad-spectrum antifungal, a vaccine candidate to eliminate a serious biological weapon threat, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.